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Abstract Recombinant human FIX concentrates (rhFIX)
are essential in the treatment and prevention of bleeding in
the bleeding disorder haemophilia B. However, due to the
complex nature of FIX production yields are low which
leads to high treatment costs. Here we report the produc-
tion of rhFIX with substantially higher yield by co-
expressing human FIX with GGCX (c-glutamyl carboxyl-
ase), VKOR (vitamin K epoxide reductase) and furin
(paired basic amino acid cleaving enzyme) in Chinese
hamster ovary (CHO) cells. Our results show that con-
trolled co-expression of GGCX with FIX is critical to
obtain high rhFIX titre, and, that co-expression of VKOR
further increased the yield of active rhFIX. Furin co-
expression improved processing of the leader peptide of
rhFIX but had a minor effect on yield of active rhFIX. The
optimal expression level of GGCX was surprisingly low
and required unusual engineering of expression vector
elements. For VKOR and furin the control of expression
was less critical and could be achieved by standard vector
element. Using our expression vectors an rhFIX-producing
clone with an expression level of up to 30 mg/L of active
rhFIX was obtained. In addition an efficient single step
purification method was developed to obtain pure and
active rhFIX with up to 94 % yield.
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Abbreviations
FIX Factor IX
CHO Chinese hamster ovary
GGCX c-Glutamyl carboxylase
Gla c-Carboxy glutamic acid
VKOR Vitamin K epoxide reductase
Furin/
PACE
Paired basic amino acid cleaving enzyme
PTMs Post-translational modifications
SDS-PAGE SDS-polyacrylamide gel electrophoresis
RT-PCR Reverse transcription polymerase chain
reaction
ELISA Enzyme-linked immunosorbent assay
MS Mass spectrometry
HPLC High performance liquid chromatograhy
1 Introduction
Coagulation factor IX (FIX) is a 55 kDa plasma protein
that has an essential role in blood coagulation. Deficiency
of FIX leads to haemophilia B, which is a bleeding disorder
characterized by impaired coagulation and increased ten-
dency to bleed. Haemophilia B is caused by mutations
affecting the X chromosome linked FIX gene, and occurs
in 1 of 30,000 male births [1, 2]. In haemophilia B patients,
bleedings are typically recurrent and often affect the knees,
ankles, and elbows. Complications include haemophilic
arthropathy, resulting in damaged, painful joints and
restricted mobility [3]. With the exception of patients with
mild forms of the disease, treatment or prevention of
bleeding episodes in haemophilia B patients is based on the
injection of coagulation factor IX concentrate [4, 5]. The
replacement coagulation factors are typically obtained
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from pooled human plasma or from recombinant prepara-
tions [3]. Administration of proteins purified from plasma
confers a risk for transmission of infectious agents, and, the
supply of suitable raw material is limited. Production of
recombinant human FIX (rhFIX) for medical use is how-
ever not a simple task, and there is currently only one
product on the market, Benefix [6]. Therefore, the avail-
ability of safe and cost-effective rhFIX concentrates still
constitutes an unmet medical need.
FIX is synthesized in liver as a zymogen which is
converted to a serine protease after activation in
plasma. Before it is secreted into plasma, FIX under-
goes several complex post-translation modifications
(PTMs), including c-carboxylation of 12 N-terminal
glutamic acid residues, N- and O-linked glycosylation,
phosphorylation, b-hydroxylation, sulfation, disulfide
bond formation, and proteolytic processing of the signal
peptide and the propeptide. Mature FIX consists of four
distinct domains: the N-terminal Gla-domain, the EGF-
like domain, the activating peptide (AP) domain and the
C-terminal serine protease domain. Among the required
PTMs is carboxylation of glutamic acid residues to
form c-glutamic acid (Gla) in the Gla domain, which is
a major challenge in obtaining high-titer expression of
fully functional rhFIX [7]. In this paper we describe
engineering of a Chinese hamster ovary (CHO) cell line
by introduction of three additional modifying enzymes
supporting c-carboxylation and proteolytic processing of
FIX, resulting in dramatically improved productivity of
fully functional rhFIX.
2 Materials and Methods
2.1 Materials
CHO-S cells, cell culture media including CD-CHO med-
ium, G418, Lipofectamine 2000, non-essential amino acids
supplement, HT supplement, human liver cDNA, mam-
malian vector pcDNA3.1V5/His, pcDNA3.1Hygro,
pcDNA3.1?, pZeoSV2?, Pfx DNA polymerase, T4
polynucleotide kinase were purchased from Invitrogen.
Konakion from Roche was used as a source of vitamin K.
Oligonucleotide DNA fragments, formic acid, Tris–HCl,
dithiothreitol and iodoacetamide were purchased from
Sigma-Aldrich and acetonitrile was from Fisher Chemical.
Trypsin was purchased from Promega and Arg-C and Lys-
C were from Roche Diagnostics. ZYMUTEST Factor IX
ELISA kit and BIOPHEN Factor IX assay kit were from
HYPHEN BioMed. ROX Factor IX activity assay kit was
from Rossix (Mo¨lndal, Sweden).
2.2 Construction of Expression Vectors
All cloning methods were according to standard methods
and/or manufacturers’ recommended procedures.
2.2.1 NopA and hglx Cloning Vectors
DNA encoding human GGCX was amplified from liver cDNA
using primers hglx5 (50-TCCGCAGAGCAATGGCGG
TGTCT-30) and hglx3 (50-CCAACATCTGGCCCCTTCA
GAACT-30). The GGCX PCR product was first cloned into the
TA-TOPO treated vector pcDNA3.1V5/His (Invitrogen).
GGCX encoding cDNA under the control of the SV40 pro-
moter was obtained by transfer of the GGCX encoding frag-
ment from pcDNA3.1V5/His TA-TOPO to the pZeoSV2?
vector, using restriction enzymes BamH1 and NotI. The
EcoRV-NotI restriction sites downstream of the GGCX insert
were removed. A blunted ClaI-BclI fragment from the resulting
pZeoSV2-GGCX plasmid (containing the SV40 promoter and
the GGCX containing insert, but not the polyadenylation site
and polyadenylation signal downstream of the GGCX encod-
ing sequence) was then cloned into the blunted DraIII restric-
tion site of pcDNA3.1?. A clone with the pSV40-GGCX
fragment inserted in tandem (same transcriptional direction)
relative to the CMV promoter was selected (pNopA). The hglx
vector was constructed similar as the NopA vector, but in order
to give higher GGCX levels the polyadenylation signal from
pZeoSV2? was included in the pSV40-GGCX-pA fragment
cloned into the blunted DraIII site of pcDNA3.1, and, a clone
with the GGCX-containing fragment in the reverse order
compared to the NopA vector was selected.
2.2.2 FIX Expression Vectors F9NopA and F9hglx
Human coagulation factor IX cDNA (GeneBank
NM_000133) was amplified from human Gene Pool liver
cDNA (Invitrogen) using oligonucleotide primers F9f.
ampl (50-CACCATGCAGCGCGTGAACATGAT-30) and
F9r.ampl (50-CCTTGGAAATCCATCTTTCATTA-30). The
human FIX fragment was PCR amplified using Pfx DNA
polymerase. The blunt-ended PCR product was phosphory-
lated using T4 polynucleotide kinase, and cloned into the
EcoRV digested and de-phosphorylated pcDNA-GGCX
vectors NopA and hglx, to give F9NopA and F9hglx,
respectively. The final expression vector sequences are
available from GenBank under accession numbers
JA237977 for F9hglx and JA237976 for F9NopA.
2.2.3 Vector VKORhygro
The VKOR coding sequence was PCR amplified from
human liver cDNA (Clontech) using primers: VF1 (50-CAC
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CATGGGCAGCACCTGGGGGA-30) and VR1 (50-
GCTCAGTGCCTCTTAGCCTT-30) and TA-TOPO cloned
into pcDNA3.1-V5/His (Invitrogen). The VKOR coding
sequence was released by HindIII and NotI and then sub-
cloned into the pcDNA3.1Hygro vector using the same
restriction enzymes to give construct pVKORhygro (Gen-
Bank accession DM079693).
2.2.4 Vector pZeoSV2-Furin
The human furin/PACE coding sequence was cloned into
pZeoSv2(?) vector (Invitrogen) using the AflII and EcoRV
restriction sites to obtain pZeoSv2-Furin (GenBank
KF886270).
The correct coding sequences of FIX, GGCX, VKOR
and furin were confirmed by DNA sequencing.
2.3 Human FIX Cell Line Development
CHO-S cells were cultured in DMEM F12 with GlutaMAX
and 10 % FBS, and transfected with linearized F9NopA or
F9hglx according to recommendations from Invitrogen.
Cells were seeded into 96-well plates with selective med-
ium containing G418 the day after transfection. Screening
for rhFIX expression was done by ELISA. The best FIX
producing clone pool was subjected to limiting dilution
cloning. During expansion clones were repeatedly screened
for rhFIX expression using an ELISA. Three clones per
construct were selected and adapted to growth in serum
free medium. After adaption, clones were evaluated and
compared based on growth properties and rhFIX expres-
sion level (using both ELISA and Western blot analysis).
The best clone N4D5 was found from the F9NopA trans-
fected cells. Clone N4D5 was then transfected with the
VKORhygro construct, linearized with SspI, and hygro-
mycin resistant clones were selected and screened for
improved productivity with both FIX activity assay and
ELISA. After limiting dilution cloning and test of pro-
ductivity the clone A2F8 was chosen for further studies.
The A2F8 cell line was transfected with pZeoSv2-Furin,
linearized by restriction enzyme SspI. After Zeocin selec-
tion, stable oligo-clonal pools were screened for improved
FIX productivity using a chromogenic FIX assay (ROX-
FIX) and clone 2F6 was selected and cryo-preserved in
CD-CHO medium with 5 % DMSO.
2.4 Quantification of rhFIX and GGCX mRNA
Expression
Recombinant hFIX-producing clones were grown at
32–37 C, in 100 mL protein free chemically defined
medium supplemented with vitamin K. Samples of
5–10 mL were collected at peak rhFIX concentration and
RNA was isolated with TrizolTM according to the protocol
supplied by the vendor (Invitrogen). The isolated RNA was
DNase I treated with the kit DNA-freeTM from Ambion.
cDNA synthesis was carried out using hexamers primers
and kit contents from SuperscriptTM First-Strand Synthesis
System for RT-PCR (Invitrogen). The RNA was analyzed
for content of human FIX and human GGCX transcripts, as
well as transcripts of the GAPDH control (house-keeping)
gene, which was used to allow comparison of different
samples.
Primers for rhFIX were:
• Forward primer; 50-AATAGTGCTGATAACAAGGT
GGTTTG-30,
• Reverse primer; 50-CACTGCTGGTTCACAGGACTT
CT-30 and
• Probe; 50-TCCTGTACTGAGGGATATCGACTTGCA
GAAAAC-30 (Amplicon length 84 bp).
Human GGCX primers were:
• Forward primer; 50-ACACCTCTGGTTCAGACCTTT
CTT-30,
• Reverse primer; 50-AATCGCTCATGGAAAGGAGTA
TTT-30 and
• Probe; 50-CAACAAAGGCTCCAGGAGATTGAAC
GC-30 (Amplicon length 86 bp)
Primers were manufactured by Operon/Qiagen and the
probes were ordered from Applied Biosystems. Rodent
GAPDH control primers and probe were also used
(Applied Biosystems; ABI # 4308318 TaqMan Rodent
GAPDH Control Reagents Protocol)-Amplicon length
177 bp. The Real-Time RT-PCR reactions were performed
on the ABI PrismTM 7700 Sequence detector, Applied
Biosystems. The expected length of the amplified PCR
products was confirmed on agarose gels.
Messenger RNA levels were found to peak at different
days depending on culture temperature and culture inocu-
lum size, but they were found to correspond well with peak
concentration of rhFIX in the culture medium.
2.5 Expression and Purification of rhFIX
Cells were inoculated into fresh CD-CHO culture medium,
supplemented with 19 HT, 19 Glutamax, 19 NEAA and
0.5 lg/mL vitamin K. Cells were cultured to a density of
5.3 9 106 cells/mL in shake flasks incubated at 37 C,
10 % CO2 and 150 rpm). Medium was then switched to an
in-house developed production medium and cell density
adjusted to 4 9 106 cells/mL. Recombinant hFIX was
expressed for 4 days at 32 C, 10 % CO2 before harvest.
The harvested culture medium was concentrated and buffer
exchanged to Buffer A0 (25 mM Hepes, 0.4 % Na-Citrate,
50 mM NaCl, pH 6.8). The sample was loaded onto a 5 mL
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HiTrap Q FF column (GE Healthcare, Sweden) pre-equil-
ibrated with Buffer A0 using A¨kta FPLC (GE Healthcare,
Sweden). After loading, the column was rinsed with buffer
A0 first, then it was washed with Buffer A1 (25 mM Tris–
HCl, 0.1 M NaCl, pH 8.0) followed by Buffer A2 (25 mM
Tris–HCl, 0.2 M NaCl, pH 8.0). The rhFIX protein was
eluted from the column with Buffer B1 (25 mM Tris–HCl,
0.1 M NaCl, 20 mM CaCl2, pH 8.0). The flow rate was
kept at 4 mL/min during the purification process. Fractions
were analyzed on SDS-PAGE gels, and fractions contain-
ing pure rhFIX protein were pooled and stored at -80 C.
2.6 Human FIX ELISA Assay
Recombinant human FIX protein in cell culture media was
determined by using ZYMUTEST Factor IX ELISA kit
according to the manufacturer’s protocol (HYPHEN Bio-
Med, France). Purified human FIX (Haematologic Tech-
nologies Inc. Essex Junction, Vermont) or BeneFIX (Wyeth)
was used as a standard.
2.7 FIX Activity Assays
Recombinant FIX activity was determined in a chromo-
genic assay using BIOPHEN Factor IX assay kit from
HYPHEN BioMed (France, Ref 221802) or ROX Factor IX
activity assay (Rossix, Mo¨lndal, Sweden) according to the
manufacture’s protocol. Commercial recombinant human
FIX (BeneFIX, Wyeth) or purified human FIX from
Haematologic Technologies Inc. (Essex Junction, Ver-
mont) was used as a standard in the activity assays. At
early stages FIX clot assay (American Diagnostica Inc.,
Stamford, Conneticut) was used, but was later replaced
with the chromogenic assays due to the convenience and
higher sensitivity of these assays.
2.8 SDS-PAGE and Western Blot Analysis
Purified recombinant FIX was analyzed on a 10 % Bis–Tris
SDS-PAGE gel under reducing condition, and the gel was
stained with InstantBlue solution (Expedeon, UK). The cell
culture media samples were run on 10 % SDS-PAGE gels,
proteins were transferred to a PVDF membrane according
to the standard method and FIX protein on the blot was
detected using a polyclonal rabbit anti-serum raised against
FIX purified from human plasma.
2.9 Mass Spectrometry Analysis
All LC/MS analyses were performed on an Agilent 1200
Series HPLC-Chip interfaced to an Agilent 6520 Q-TOF
mass spectrometer. Chromatography was performed on an
HPLC-Chip that had a 40 nL enrichment column and a
43 mm 9 75 lm analytical column packed with ZORBAX
300SB, 5 lm particles. A C18 column was used for peptide
analysis and the full-length protein was analyzed using a
C8 column. Samples were loaded onto the enrichment
column at a flow rate of 4 lL/min with Eluent A (97.5 %
water, 2.5 % acetonitrile and 0.1 % formic acid). Elution
was performed from the analytical column using a gradient
from 5 % Eluent B (95 % acetonitrile, 5 % water and
0.1 % formic acid) to 65 % B in 20 min, followed by a step
gradient to 95 % B before equilibration with 5 % B. The
flow rate used during separation was 0.3 lL/min.
Before peptide mapping the cysteines were reduced
using 10 mM dithiothreitol at 95 C for 5 min and allowed
to cool down to RT followed by alkylation with 55 mM
iodoacetamide in the dark for 60 min. Proteins were
digested with trypsin, Arg-C or Lys-C at 37 C with an
enzyme-to-substrate ratio (w/w) of 1:20 overnight accord-
ing to descriptions given by the manufacturers. The peptide
solutions were subjected to HPLC-Chip-MS/MS analysis.
The full-length protein was diluted with 0.1 % formic acid
in water to a final concentration of 1 pmol/lL and sub-
jected to HPLC-Chip-MS analysis.
2.10 c-Carboxylation Analysis of Glutamic Acid
Residues
In this study the content of c-carboxylated glutamic acid
residues was examined using peptide mapping and mass
spectrometry. After alkylation of the cysteines and treat-
ment with endoproteinase Lys-C of rhFIX, the N-terminal
amino acid sequence 1–43 was formed. This amino acid
sequence contains all 12 potential glutamic acid residues
available for c-carboxylation in FIX. The 1–43 peptide
contained different numbers of c-carboxylated glutamic
acid residues. When trypsin or endoproteinase Arg-C were
used as proteases there was information about the content
of c-carboxylated glutamic acid in position Glu-40.
3 Results
3.1 Generation of Stable rhFIX Cell Line
Factor IX (FIX) is a protein undergoing many different
post-translational modifications to be fully functional
(Fig. 1a), including carboxylation of 12 glutamic acid
residues in the N-terminal Gla domain. Achieving suffi-
cient c-carboxylation is one of the major challenges in
high-tire production of recombinant human FIX (rhFIX). In
this study, we have employed a new strategy for generating
a production cell line for functional rhFIX. Our cell line
development process involved three steps where modifi-
cation enzymes were added to generate the required post-
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translational modifications. An overview of the FIX cell
line development work is outlined in Fig. 2.
3.1.1 Co-expression of FIX with GGCX in CHO Cells
In the first step of our cell line development, we co-
expressed FIX and GGCX. CHO-S cells were transfected
with either F9NopA or F9hglx, two vectors carrying FIX
and GGCX cDNA and engineered to obtain low levels of
GGCX expression (Fig. 2). Analyses of the resulting
clones showed that the F9NopA vector gave the most
productive clones and also gave the lowest expression level
of GGCX. From Real-Time RT-PCR analyses we found
that, although human GGCX and rhFIX mRNA expression
varied with culture time and conditions, the FIX:GGCX
mRNA ratios were approximately the same for each clone.
For the best rhFIX-producing clone N4D5 the ratio was
approximately 45:1. Analyses of the best clone obtained
with the F9hglx vector, P1G9, gave a lower ratio of
approximately 4.5:1. This clone produced only 20 % of the
amount rhFIX produced by N4D5 measured by FIX clot
assay, even though the amount of rhFIX mRNA per cell
was similar in these two clones.
Three rounds of shake flask expression experiments
exploring different culture condition were made to evaluate
growth characteristics as well as rhFIX expression of the
chosen clones. Total rhFIX protein yield, including
incompletely carboxylated and non-active rhFIX, was
estimated by Western blotting to be at least 30 mg/L for
the best clone, N4D5 (results not shown). The amount of
active rhFIX was estimated by FIX clot assay to approxi-
mately 7 mg/L, which is a clear improvement compared to
previously reported rhFIX expression levels obtained under
comparable conditions which yielded approximately
1.5 mg/L active rhFIX [8]. Our results showed that con-
trolled GGCX expression improved rhFIX productivity,
although a large share of the rhFIX protein was still under-
carboxylated.
3.1.2 Super-Transfection of Clone N4D5 with Vector
Carrying VKOR cDNA
To improve the share of active rhFIX the N4D5 clone was
stably transfected with the linearized VKORhygro con-
struct in which VKOR expression is controlled by the
CMV promoter (Fig. 2). Obtained clones were screened for
A
S P Gla EGF EGF AP Serine Protease Domain
1 46 145 180 415
B
MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG KLEEFVQGNL 14
ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDGDQCESN PCLNGGSCKD DINSYECWCP 74
FGFEGKNCEL DVTCNIKNGR CEQFCKNSAD NKVVCSCTEG YRLAENQKSC EPAVPFPCGR 134
VSVSQTSKLT RAETVFPDVD YVNSTEAETI LDNITQSTQS FNDFTRVVGG EDAKPGQFPW 194
QVVLNGKVDA FCGGSIVNEK WIVTAAHCVE TGVKITVVAG EHNIEETEHT EQKRNVIRII 254
PHHNYNAAIN KYNHDIALLE LDEPLVLNSY VTPICIADKE YTNIFLKFGS GYVSGWGRVF 314
HKGRSALVLQ YLRVPLVDRA TCLRSTKFTI YNNMFCAGFH EGGRDSCQGD SGGPHVTEVE 374
GTSFLTGIIS WGEECAMKGK YGIYTKVSRY 514TLKTKEKIWNV
Furin
Fig. 1 Schematic presentation of human FIX domain structure and
its amino acid sequence. Arabic numbers 1–415 indicate amino acid
positions in the mature FIX protein. a FIX domain structure. The
signal peptide (S) and the propeptide (P) are removed to form mature
FIX. In the mature part of FIX the c-carboxy glutamic acid domain
(Gla), epidermal growth factor like domain (EGF), the activating
peptide (AP) and the Serine Protease Domain, which is the FIX
catalytic domain, are indicated. b Amino acid sequence of human
FIX. The furin cleavage site is indicated and symbols above amino
acid sequence indicate different post translational modifications; open
star c-carboxy glutamic acids, filled star b-hydroxylation, open
diamond O-linked glycosylations, filled diamond N-linked glycosy-
lations, filled circle sulfation, open circle phosphorylation. Peptide
mapping by mass spectrometry of recombinant FIX protein showed a
total sequence coverage of 94 % (underlined) when endoproteinase
Lys-C, Arg-C and trypsin were used. The signal peptide amino acids
are in lilac font and the propeptide amino acids are in red (Color
figure online)
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FIX productivity and VKOR expression was confirmed by
RT-PCR (data not shown). Shake flask cultures from the
best clone obtained, A2F8, had a total titer of rhFIX of
80–90 mg/L estimated by ELISA and produced up to
30 mg/L active rhFIX, determined by a chromogenic FIX
activity assay (Fig. 3). The active rhFIX level obtained
from A2F8 cells is significantly higher than previous clones
(Table 1).
3.1.3 Super-Transfection of Clone A2F8 with Furin
Analysis of purified rhFIX protein from A2F8 cells
showed that the propeptide of rhFIX was incompletely
removed; about 30 % of the rhFIX still contained the
propeptide. furin, also called PACE, is a protein that can
proteolytically cleave propeptides, and has previously
been reported to be involved in the processing of the FIX
propeptide and found to improve FIX productivity in
CHO cells [8]. To evaluate if processing of the rhFIX
propeptide in clone A2F8 could be improved by co-
expression of furin, the A2F8 cells were transfected with
the linearized vector pZeoSv2-Furin DNA (Fig. 2), in
which the furin cDNA is controlled by the SV40 pro-
motor. After transfection and selection in Zeocin-con-
taining medium, stable oligo-clonal pools were screened
for improved rhFIX productivity using a chromogenic
FIX activity assay (ROX-FIX). Clone 2F6 was found to
have higher FIX activity. Recombinant hFIX from 2F6
shake flask cultures was partially purified via Q pseudo-
affinity chromatography and subjected to N-terminal
sequencing. Results showed that the propeptide of rhFIX
was precisely and completely processed; showing that co-
expression of furin improved propeptide processing of
rhFIX.
Fig. 2 Overview of rhFIX cell line generation and maps of expres-
sion vectors. CHO-S cells were first transfected with the vectors
F9NopA or F9hglx carrying FIX and GGCX cDNA. After screening
of approximately 3,000 clones for FIX expression by a FIX-ELISA
assay, the N4D5 clone originating from the F9NopA transfection was
identified. This clone was then super-transfected with the vector
VKORhygro carrying VKOR cDNA, and approximately 1,500 clones
were screened for increased FIX activity. In the third step, the stable
cell line A2F8 was super-transfected with the vector pZeoSV2-Furin
carrying furin cDNA and approximately 600 clones were screened for
increased FIX activity in order to identify the stable clone 2F6
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3.2 One-step Purification of Recombinant Human FIX
Different purification strategies for recombinant hFIX
have been described in the literature, either using multi-
steps of chromatography [9] or an affinity column with
immobilized FIX antibody [10]. In this study, a simple and
economical one-step purification method has been devel-
oped using ion-exchange chromatography (QFF).
Recombinant FIX producing cells were grown in an in-
house chemical defined serum-free medium with supple-
ments (NEAA, GlutaMAX and Konakion). After culti-
vation, cell culture medium was harvested, concentrated
and purified as described in Sect. 2. During purification
development, it was found that rhFIX bound relatively
strong to the HiTrap Q column, at a salt concentration of
250 mM, rhFIX still remained on the column. The active
rhFIX protein was eluted from the column with a buffer
containing 100 mM NaCl and 20 mM CaCl2, which
released rhFIX protein from the column via Ca2?-binding
induced conformation change of FIX. The buffer used
eluted little contaminating protein, and most of the under-
carboxylated rhFIX remained on the column. An example
of the chromatography is shown in Fig. 4a. The purity of
rhFIX protein was estimated to be more than 90 % pure
based on SDS-PAGE analysis (Fig. 4b) and the yield of
rhFIX was 94 %.
Our results show that active recombinant FIX can be
efficiently purified from cell culture media via a single-step
AIEX chromatography method with a high yield.
3.3 Characterization of Recombinant FIX
Human FIX protein consists of 415 amino acids with a
theoretical molecular weight of 46,578 Da for the amino
acid sequence alone, but its apparent MW is about 55 kDa
due to numerous post-translational modifications. Recom-
binant human FIX was produced as a single chain zymo-
gen. The purified rhFIX was analyzed on SDS-PAGE with
an apparent molecular weight of 55 kDa (Fig. 4b), which is
in good agreement with data reported previously [7]. Mass
spectrometry analysis of rhFIX showed a molecular weight
of about 54,770 Da. A broad peak was observed consistent
with the complex post-translational modifications, for
example different glycosylated forms (data not shown).
Peptide mapping analysis of rhFIX showed a total sequence
coverage of 94 % (underlined in Fig. 1b) when endopro-
teinase Lys-C, Arg-C and trypsin were used. Both N- and
C-terminal peptides were identified in the analyses
(Fig. 1b). Plasma derived FIX contains 12 c-carboxylated
glutamic acid residues in its N-terminal Gla domain, and
the c-carboxylation modification of these residues is criti-
cal for FIX’s maturation and function [11]. The content of
c-carboxylation of purified rhFIX was analyzed by MS. All
observed c-carboxylated forms for the N-terminus (amino
acid 1–43) are listed in Table 2. The three dominant forms
have 9, 10 and 11 c-carboxyglutamic acids. About 70 % of
the purified rhFIX contained 10 or more c-carboxyglutamic
acids. MS data also showed that Glu-40 was c-carboxyl-
ated to a very low extent.
4 Discussion
Co-expression of modification enzymes to improve post-
translational modifications of FIX has been attempted
before with variable success. Co-expression of PACE (a
secreted soluble form of furin) is utilised in the produc-
tion of BeneFIX, and has been shown to improve pro-
ductivity of FIX in CHO cells. On the other hand
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Fig. 3 Recombinant human FIX production in shake flask culture.
Cells were inoculated and cultivated as described in Sect. 2. FIX
activity in the culture samples were determined by the ROX-FIX
chromogenic FIX activity assay. Data are from one representative
experiment with clone A2F8 grown at the most favourable conditions
identified
Table 1 Best rhFIX yields obtained during cell line development
Clone Expression vectors Active rhFIX
(mg/L)
Culture condition
P1G9 F9hglx 1.3 Spinner bottle
N4D5 F9NopA 4 Small shake
flask
N4D5 F9NopA 7.1 Spinner bottle
A2F8 F9NopA ? VKORhygro 30 Shake flask
All cell cultures were performed at small scale (\100 mL) and FIX
activity was measured by FIX clot assay (spinner bottles) or a chro-
mogenic FIX assay (shake flasks) as described in Sect. 2
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presence of PACE expression, co-expression of GGCX
together with FIX failed to improve secreted FIX specific
activity [12, 13].
We believe that co-expression of modification enzymes
need careful considerations for an optimal result. The
intra-cellular location of modification enzymes and inter-
action with endogenous host cell machinery may require
that the expression of added enzymes are restricted or
controlled. With the work presented here, we have dem-
onstrated that the productivity of rhFIX in mammalian
cells can be dramatically improved by co-expressing
enzymes to support c-carboxylation and proteolytic pro-
cessing. Our data suggest that controlled co-expression of
GGCX gave the increase in total product titre. The level of
GGCX expression giving the highest titre of FIX was
surprisingly low; real-time PCR analyses indicated that
less than 50 GGCX mRNA transcripts per cell were
formed using the NopA expression vector, which gave the
highest total rhFIX titre and an improved yield of active
rhFIX.
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Fig. 4 a QFF pseudo-affinity
chromatography of rhFIX. The
culture harvest (970 mL) was
concentrated, then buffer
exchanged to Buffer A0 (final
volume 147 mL) and filtrated
before loading onto a pre-
equilibrated Q ion-exchange
column. After washing with A1
and A2 buffers, the rhFIX
protein was eluted by A3 buffer.
b SDS-PAGE analysis of
purified rhFIX protein. Purified
and concentrated rhFIX was
analysed together with Benefix
on a 10 % SDS-PAGE under
reducing condition. The gel was
stained with InstantBlue
solution. Lane 1 Novex Sharp
protein standard, lane 2–3




There are 12 possible c-
carboxy glutamic acid residues
(GLA) in total
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The co-expression of VKOR improved c-carboxylation
but did not increase total rhFIX titre, which is in agreement
with previously published data [14].We noted that the
addition of VKOR improved growth properties of the FIX
expressing clones, most notably by improving the survival
of clones during the limiting dilution cloning procedures,
and gave faster growth rates. The requirement of vitamin K
addition to the culture medium decreased significantly and
it was no longer necessary to feed extra vitamin K to the
VKOR-transfected clones during rhFIX production. This
suggests that the addition of VKOR has additional benefits
in that vitamin K was efficiently recycled and accumulation
of vitamin K epoxide, which could potentially be toxic to
the host cells, was avoided.
Co-expression of furin significantly enhanced propep-
tide processing of FIX, which may affect specific activity.
However, with the work reported here we were not able to
demonstrate a clear impact on specific activity with or
without the propeptide present. The fact that furin
improved productivity of active FIX may just as well be
attributable to a more efficient secretion of the protein. We
have co-expressed the full-length form of furin, which is
located in the ER and may therefore take part in improving
the overall processing of rhFIX.
Characterization of rhFIX produced by our methods
showed that rhFIX had the expected molecular weight and
was c-carboxylated to a high degree. In comparison with
plasma derived FIX which is fully c-carboxylated having 12
glutamic acid residues in the Gla domain and BeneFIX having
10 or more c-carboxyglutamic acid residues, c-carboxylation
was lower in our FIX [7, 15]. However, earlier studies have
shown that c-carboxylation at Glu-36 and Glu-40 were not
important for FIX function [16] suggesting that the c-car-
boxylation of our rhFIX may be sufficient for high clotting
activity. Further purification can also be done in order to
remove under-carboxylated species. The first EGF domain of
plasma derived FIX has three different post-translational
modifications, two O-linked glycosylations on serine residues
53 and 61 [17, 18] and b-hydroxylation modification on
aspartic acid at position 64 [19]. Mass spectometric studies
showed that our rhFIX was b-hydroxylated on aspartic acid to
about 40 % at position 64. This result is similar to what have
been reported earlier for both plasma derived FIX and Bene-
FIX [15]. Also O-linked glycosylations in the first EGF
domain of our rhFIX were studied by MS and showed that Ser-
53 had a uniform O-glycosylation, Xyl-Xyl-Glc, whereas Ser-
61 had three different O-linked forms, NeuAc-Gal-GlcNac-
Fuc, Gal-GlcNAc-Fuc, and Fuc. These results are in line with
what have been reported for other recombinant FIX produced
[15, 20].
In summary, we hope that the expression strategies and
results presented in this paper will contribute to the
development of affordable coagulation factor products.
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